175 related articles for article (PubMed ID: 22251700)
21. Viral and nonviral uses of imiquimod: a review.
Gupta AK; Cherman AM; Tyring SK
J Cutan Med Surg; 2004; 8(5):338-52. PubMed ID: 15868314
[TBL] [Abstract][Full Text] [Related]
22. [Application of imiquimod and resiquimod in dermatology].
Xu KJ; Liu YH
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2006 Jun; 28(3):445-7. PubMed ID: 16900654
[TBL] [Abstract][Full Text] [Related]
23. Imiquimod is a strong inhibitor of tumor cell-induced angiogenesis.
Majewski S; Marczak M; Mlynarczyk B; Benninghoff B; Jablonska S
Int J Dermatol; 2005 Jan; 44(1):14-9. PubMed ID: 15663652
[TBL] [Abstract][Full Text] [Related]
24. Imiquimod in basal cell carcinoma: how does it work?
Dummer R; Urosevic M; Kempf W; Hoek K; Hafner J; Burg G
Br J Dermatol; 2003 Nov; 149 Suppl 66():57-8. PubMed ID: 14616353
[TBL] [Abstract][Full Text] [Related]
25. Imiquimod; an international update on therapeutic uses in dermatology.
Tyring S; Conant M; Marini M; Van Der Meijden W; Washenik K
Int J Dermatol; 2002 Nov; 41(11):810-6. PubMed ID: 12453012
[TBL] [Abstract][Full Text] [Related]
26. Immune-mediated changes in actinic keratosis following topical treatment with imiquimod 5% cream.
Torres A; Storey L; Anders M; Miller RL; Bulbulian BJ; Jin J; Raghavan S; Lee J; Slade HB; Birmachu W
J Transl Med; 2007 Jan; 5():7. PubMed ID: 17257431
[TBL] [Abstract][Full Text] [Related]
27. Plasmacytoid dendritic cells, a role in neoplastic prevention and progression.
Lombardi VC; Khaiboullina SF; Rizvanov AA
Eur J Clin Invest; 2015 Jan; 45 Suppl 1():1-8. PubMed ID: 25524580
[TBL] [Abstract][Full Text] [Related]
28. New insights into imiquimod's mechanisms of action.
Martín-García RF
J Drugs Dermatol; 2004; 3(3):247-9. PubMed ID: 15176157
[TBL] [Abstract][Full Text] [Related]
29. Toll-like receptor 7 agonists and skin.
Novak N; Yu CF; Bieber T; Allam JP
Drug News Perspect; 2008 Apr; 21(3):158-65. PubMed ID: 18560614
[TBL] [Abstract][Full Text] [Related]
30. [Clinical remission of classic Kaposi sarcoma with topical 5% imiquimod].
Echeverría-García B; Sanmartín O; Guillén C
Actas Dermosifiliogr; 2010 Mar; 101(2):181-2. PubMed ID: 20223165
[No Abstract] [Full Text] [Related]
31. Lupus erythematosus-like imiquimod reaction: a diagnostic pitfall.
Barr KL; Konia TH; Fung MA
J Cutan Pathol; 2011 Apr; 38(4):346-50. PubMed ID: 20726930
[TBL] [Abstract][Full Text] [Related]
32. Nature of inflammatory infiltrate in superficial cutaneous malignancies during topical imiquimod treatment.
Wolf IH; Kodama K; Cerroni L; Kerl H
Am J Dermatopathol; 2007 Jun; 29(3):237-41. PubMed ID: 17519620
[TBL] [Abstract][Full Text] [Related]
33. Locally administered TLR7 agonists drive systemic antitumor immune responses that are enhanced by anti-CD40 immunotherapy.
Broomfield SA; van der Most RG; Prosser AC; Mahendran S; Tovey MG; Smyth MJ; Robinson BW; Currie AJ
J Immunol; 2009 May; 182(9):5217-24. PubMed ID: 19380767
[TBL] [Abstract][Full Text] [Related]
34. Mechanisms underlying imiquimod-induced regression of basal cell carcinoma in vivo.
Urosevic M; Maier T; Benninghoff B; Slade H; Burg G; Dummer R
Arch Dermatol; 2003 Oct; 139(10):1325-32. PubMed ID: 14568837
[TBL] [Abstract][Full Text] [Related]
35. Topical imiquimod treatment of a cutaneous melanoma metastasis.
Steinmann A; Funk JO; Schuler G; von den Driesch P
J Am Acad Dermatol; 2000 Sep; 43(3):555-6. PubMed ID: 10954675
[No Abstract] [Full Text] [Related]
36. The role of topical immune response modifiers in skin cancer.
Woodmansee C; Pillow J; Skinner RB
Drugs; 2006; 66(13):1657-64. PubMed ID: 16978032
[TBL] [Abstract][Full Text] [Related]
37. Tumoricidal activity of TLR7/8-activated inflammatory dendritic cells.
Stary G; Bangert C; Tauber M; Strohal R; Kopp T; Stingl G
J Exp Med; 2007 Jun; 204(6):1441-51. PubMed ID: 17535975
[TBL] [Abstract][Full Text] [Related]
38. Topical treatment of melanoma metastases with imiquimod, plus administration of a cancer vaccine, promotes immune signatures in the metastases.
Mauldin IS; Wages NA; Stowman AM; Wang E; Olson WC; Deacon DH; Smith KT; Galeassi N; Teague JE; Smolkin ME; Chianese-Bullock KA; Clark RA; Petroni GR; Marincola FM; Mullins DW; Slingluff CL
Cancer Immunol Immunother; 2016 Oct; 65(10):1201-12. PubMed ID: 27522582
[TBL] [Abstract][Full Text] [Related]
39. Off-label indications for imiquimod.
Ganjian S; Ourian AJ; Shamtoub G; Wu JJ; Murase JE
Dermatol Online J; 2009 May; 15(5):4. PubMed ID: 19624982
[TBL] [Abstract][Full Text] [Related]
40. Topical rather than intradermal application of the TLR7 ligand imiquimod leads to human dermal dendritic cell maturation and CD8+ T-cell cross-priming.
Fehres CM; Bruijns SC; van Beelen AJ; Kalay H; Ambrosini M; Hooijberg E; Unger WW; de Gruijl TD; van Kooyk Y
Eur J Immunol; 2014 Aug; 44(8):2415-24. PubMed ID: 24825342
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
